T. Rowe Price takes 5.9% PROCEPT BioRobotics (PRCT) position
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 3,271,408 shares of PROCEPT BioRobotics Corp common stock, representing 5.9% of the outstanding class as of the reported date. T. Rowe Price has sole voting and dispositive power over all these shares.
The firm states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PROCEPT. It also expressly denies being the beneficial owner of the securities beyond what is required for this disclosure.
Positive
- None.
Negative
- None.
FAQ
What stake does T. Rowe Price hold in PROCEPT BioRobotics (PRCT)?
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 3,271,408 PROCEPT BioRobotics common shares, representing 5.9% of the class. This gives the firm a significant institutional position while remaining below typical 10% insider thresholds.
Does T. Rowe Price control PROCEPT BioRobotics (PRCT) through this ownership?
T. Rowe Price states the shares were acquired and are held in the ordinary course of business, not to change or influence control. The firm certifies it is not participating in any control-related transactions, and it expressly denies beneficial ownership beyond this disclosure.
How much voting power does T. Rowe Price have in PROCEPT BioRobotics (PRCT)?
T. Rowe Price reports sole voting power over 3,271,408 PROCEPT BioRobotics common shares. It has no shared voting power, indicating that decisions on how these shares are voted rest solely with T. Rowe Price Investment Management, Inc.
What type of investor is T. Rowe Price in relation to PROCEPT BioRobotics (PRCT)?
T. Rowe Price Investment Management, Inc. files as an institutional investor, including as an investment adviser under SEC rules. It indicates the holdings are managed professionally, consistent with a typical asset management role rather than an activist or control-seeking investor.
Why is T. Rowe Price’s 5.9% holding in PROCEPT BioRobotics (PRCT) disclosed?
The 5.9% stake exceeds the 5% ownership threshold that triggers beneficial ownership reporting. When an institutional investor crosses this level, it must publicly disclose its position, voting power, and intentions regarding control, as T. Rowe Price has done here.